Physician profile
Neda Khaghan
NPI 1538180427
$7,122.92
in general payments reported to CMS, 2019-2025
32 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,445 · 2020: $881 · 2021: $314 · 2022: $889 · 2023: $1,506 · 2024: $1,374 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,594.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,634.95 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,054.62 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $948.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $655.78 | 2019-2025 | Entyvio, Gattex |
| Ferring Pharmaceuticals INC. | $354.68 | 2019-2025 | Rebyota |
| Janssen Biotech, INC. | $334.74 | 2019-2025 | Simponi, Remicade, Simponi Aria |
| Genzyme Corporation | $323.98 | 2022-2025 | |
| Lilly USA, LLC | $281.87 | 2024-2025 | Omvoh, Zepbound |
| Allergan, INC. | $234.10 | 2019-2020 | |
| Ardelyx, INC. | $195.76 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $185.59 | 2022-2025 | Ocaliva |
| Celgene Corporation | $144.00 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $100.44 | 2019-2021 | |
| Gilead Sciences, INC. | $89.37 | 2019 | |
| Madrigal Pharmaceuticals | $83.61 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $81.05 | 2019 | |
| Redhill Biopharma INC. | $71.32 | 2020-2024 | Talicia |
| Regeneron Healthcare Solutions, INC. | $63.91 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $46.23 | 2019-2022 | |
| Amgen INC. | $46.10 | 2023 | Amjevita, Avsola |
| Qol Medical, LLC | $28.80 | 2020 | |
| Echosens North America, INC. | $25.00 | 2019 | |
| Exact Sciences Corporation | $22.49 | 2023 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $20.13 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Shire North American Group INC | $18.16 | 2019 | |
| Shionogi INC | $15.92 | 2020 | |
| Braintree Laboratories, INC. | $15.61 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.06 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $13.48 | 2019 | |
| Endo Pharmaceuticals INC. | $11.99 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $6.76 | 2023 | Endoink |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neda Khaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.